These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 28105368)
1. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368 [TBL] [Abstract][Full Text] [Related]
2. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516 [No Abstract] [Full Text] [Related]
3. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition. Sodji Q; Klein K; Sravan K; Parikh J J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004 [TBL] [Abstract][Full Text] [Related]
4. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases. Carter SA; Walker AN J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619 [TBL] [Abstract][Full Text] [Related]
6. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663 [TBL] [Abstract][Full Text] [Related]
7. Cystic presentation of a renal medullary carcinoma in a young woman. Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M Urologia; 2015; 82(2):124-6. PubMed ID: 25451881 [TBL] [Abstract][Full Text] [Related]
8. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series. Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708 [TBL] [Abstract][Full Text] [Related]
9. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223 [TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Yang XJ; Sugimura J; Tretiakova MS; Furge K; Zagaja G; Sokoloff M; Pins M; Bergan R; Grignon DJ; Stadler WM; Vogelzang NJ; Teh BT Cancer; 2004 Mar; 100(5):976-85. PubMed ID: 14983493 [TBL] [Abstract][Full Text] [Related]
11. Renal Medullary Carcinoma: a Report of the Current Literature. Blas L; Roberti J; Petroni J; Reniero L; Cicora F Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488 [TBL] [Abstract][Full Text] [Related]
12. Renal medullary carcinoma and ABL gene amplification. Simpson L; He X; Pins M; Huang X; Campbell SC; Yang XJ; Perlman EJ; Bergan RC J Urol; 2005 Jun; 173(6):1883-8. PubMed ID: 15879768 [TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Renal Medullary Carcinoma. Su Y; Hong AL Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102 [TBL] [Abstract][Full Text] [Related]
14. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856 [TBL] [Abstract][Full Text] [Related]
15. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma. Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066 [TBL] [Abstract][Full Text] [Related]
16. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323 [TBL] [Abstract][Full Text] [Related]
17. Renal medullary carcinoma: A national analysis of 159 patients. Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report. Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350 [TBL] [Abstract][Full Text] [Related]
19. Renal medullary carcinoma in a white adolescent with sickle cell trait. Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963 [TBL] [Abstract][Full Text] [Related]